Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

307
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
307
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

484
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
484
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.9K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

695
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
695
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

736
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
736
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

1.0K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benzodiazepine Tapering: Evidence Limitations and Research Recommendations.

Journal of addiction medicine·2026
Same author

Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits.

Journal of general internal medicine·2025
Same author

Recurrent Clozapine-Associated Pneumonia: A Case Report.

Journal of clinical psychopharmacology·2024
Same author

Clinical pearls for the management of duloxetine patients with medical comorbidities.

The mental health clinician·2024
Same author

2023 MHC Awards and Recognition.

The mental health clinician·2024
Same author

Relative exposure to psychiatric conditions and medications in pharmacy education.

Currents in pharmacy teaching & learning·2023

Related Experiment Video

Updated: Sep 27, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K

Valproate: Not All Boxed Warnings Are Created Equal.

Carolanne Wartman1, Amy VandenBerg1

  • 1College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.

The Annals of Pharmacotherapy
|April 8, 2022
PubMed
Summary
This summary is machine-generated.

Valproate carries a significant fetal risk, with an 8.6% malformation rate in exposed infants. Current monitoring for liver and pancreatic risks may overshadow this more common and severe teratogenic danger.

Keywords:
anticonvulsantsdrug monitoringhepatotoxicitypancreatitispregnancy/drug effectsteratogens

More Related Videos

Seizure Activity Induced by Electroshock in Drosophila Larvae
06:10

Seizure Activity Induced by Electroshock in Drosophila Larvae

Published on: June 6, 2025

446
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.0K

Related Experiment Videos

Last Updated: Sep 27, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K
Seizure Activity Induced by Electroshock in Drosophila Larvae
06:10

Seizure Activity Induced by Electroshock in Drosophila Larvae

Published on: June 6, 2025

446
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.0K

Area of Science:

  • Pharmacology and Toxicology
  • Obstetrics and Gynecology
  • Drug Safety

Background:

  • Valproate (VPA) labeling has evolved, with boxed warnings for teratogenicity, hepatotoxicity, and pancreatitis.
  • Recent updates emphasize fetal risks, necessitating a review of evidence and current recommendations.

Purpose of the Study:

  • To analyze evidence concerning valproate's boxed warnings, focusing on teratogenicity, hepatotoxicity, and pancreatitis.
  • To evaluate the adequacy of current monitoring recommendations in light of the evidence.

Main Methods:

  • Comprehensive literature search of PubMed, Cochrane Central Register, Google Scholar, and manufacturer data (1963-February 2022).
  • Inclusion of English-language, human studies and product labeling.
  • Search terms included valproate, valproic acid, Depakote, teratogenicity, birth defects, fetal risk, hepatotoxicity, and pancreatitis.

Main Results:

  • In utero valproate exposure poses a significant fetal risk, with an 8.6% malformation rate in 360 North American women.
  • Hepatotoxicity and pancreatitis risks are substantially lower in the general population (1/20,000 and 1/40,000) compared to specific patient groups on valproate (1/500).
  • Current US labeling recommends contraception for women of childbearing age.

Conclusions:

  • Overemphasis on monitoring for hepatotoxicity and pancreatitis may detract from the more prevalent and severe risk of fetal harm.
  • Clinicians must prioritize discussing and documenting fetal risks with patients.
  • Consideration should be given to revising monitoring recommendations, potentially through Risk Evaluation and Mitigation Strategy (REMS) programs, to enhance focus on fetal risks and incorporate risk factors for hepatotoxicity/pancreatitis.